Læknablaðið - 15.10.2003, Page 56

G E Ð R 0 F
Sjúklingar eru í meiri hættu á að fá

rxi^
r Udi
Fyrsta nýja geðrofslyfið á
langverkandi formi
Veitir sjúklingum langtíma
stöðugleika með samfelldum
Fyrir sjuklinga sem þurfa langtíma meðferð
morí oroArnfc l\/fi11 m1-3
J r WV » IV/I IUIUU IW ... II I
athafna daglegs Iffs5-6
References: 1. Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-lerm safety of long-acting risperidone microspheres. Poster presented at: nth Biennial Winter Workshop on Schizophrenia; February 2a-March 1 2002;
aaS’ ^W,tzerland-2- Kane ), Eerdekens M Keith S et a . Effícacy and safety of a novel long-acting risperidone microspheres formulation. Poster presented at: nth Biennial Winter Workshop on Schizophrenia: February
24-March i, 2002; Davos, Switzerland. 3- Chue P, Eerdekens M, Augustyns B, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Poster presented at: nth Biennial Winter
Workshop on Schizophrema; February 2Z,-March 1, 2002; Davos, Switzerland. 4. Data on file, Janssen Pharmaceutica. 5. Data on file, Janssen Pharmaceutica. 6. Data on file, lanssen Pharmaceutica